Market & Regulation
GSK and Relation Therapeutics in $110M AI Drug Discovery Deal
AI Newshigh confidence
Why it matters
- →The collaboration emphasizes the integration of biological data with AI for drug discovery.
- →Specialized datasets are becoming crucial for developing robust AI models in biopharma.
- →The partnership reflects a growing trend of AI-driven approaches in pharmaceutical research.
GSK has partnered with Relation Therapeutics in a research collaboration valued at up to $110 million, focusing on AI-assisted drug discovery. Relation will generate extensive datasets on human cellular responses to genetic changes and drug interventions, which will be used to train AI models for drug target identification. This agreement highlights the importance of biological data in AI model development, building on previous collaborations between the two companies. The partnership reflects a broader industry trend towards specialized datasets in biopharma, essential for advancing AI applications in drug discovery.
Read originalThe story around this
Earlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
More in Market & Regulation
© TechCrunch AIMarket & Regulationother
Judge allows NAACP lawsuit over xAI pollution to proceed
xAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
TechCrunch AI
© TechCrunch AI